Drug Search Results

CP-868,596

Alternative Names: cp-868,596, cp868,596, cp 868,596
Latest Update: 2024-07-03
Latest Update Note: Clinical Trial Update

Product Description

crenolanib besylate in newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent high-grade glioma (HGG). (Sourced from: https://meetinglibrary.asco.org/record/91991/abstract)

Mechanisms of Action: FLT3 Inhibitor,PGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Arog
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Myeloid Leukemia

Phase 1: Oncology Solid Tumor Unspecified

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
ARO-009	P2	Completed	Acute Myeloid Leukemia	2022-05-01	51%
A5301005	P1	Completed	Oncology Solid Tumor Unspecified	2008-06-01

Recent News Events

Date	Type	Title
04/05/2024	PubMed	The relationships of platelet-derived growth factor, microvascular proliferation, and tumor cell proliferation in canine high-grade oligodendrogliomas: Immunohistochemistry of 45 tumors and an AFOB-01 xenograft mouse model.
03/03/2024	PubMed	Defective Biomechanics and Pharmacological Rescue of Human Cardiomyocytes with Filamin C Truncations.
02/02/2024	PubMed	Filamin C Deficiency Impairs Sarcomere Stability and Activates Focal Adhesion Kinase through PDGFRA Signaling in Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions